Status:
UNKNOWN
Respiratory Variation of Superior Vena Cava in Transthoracic View as a Fluid Responsiveness Predictor
Lead Sponsor:
University of Chile
Conditions:
Shock
Eligibility:
All Genders
18+ years
Brief Summary
Fluid evaluation is relevant in critical care. Cardiac ultrasound is the first line of evaluation in hemodynamic characterization of patients in shock, to tailor therapy. Fluid responsiveness predict...
Detailed Description
Prospective evaluation of diameter variability of the superior vena cava by transthoracic echocardiography as fluid responsiveness predictor in critically ill patients: Background Fluid administratio...
Eligibility Criteria
Inclusion
- Patients \>18 years,
- Hospitalized in the Intensive Care Unit (ICU) with length of stay under 7 days
- Under positive pressure ventilation with no inspiratory effort,
- With hemodynamic instability (defined as abnormal peripheral perfusion or increased blood lactic or vasopressor infusion of norepinephrine \>0.1 ug/kg/min to achieve adequate mean arterial pressure)
Exclusion
- Spontaneous ventilatory effort
- Lack of venous access
- Carrier of carbapenemase or clostridium difficile
- Lack of adequate superior vena cava (SVC) window (not allowing M-mode during both respiratory phases)
- Severe aortic regurgitation
- Impossibility to measure LVOT-VTI
- Extracorporeal membrane oxygenation.
Key Trial Info
Start Date :
March 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05211765
Start Date
March 7 2021
End Date
March 1 2024
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Clínico Universidad de Chile
Santiago, Santiago Metropolitan, Chile, 8380420